Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
TAVR Highlights: A new implantation technique | The world's first polymeric valve | Planning ahead | Oversizing boosts survival
Wednesday, March 11, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: TAVR

Cardiologists perform first TAVR of its kind by anchoring valve to crushed stent

The patient, 78, presented with severe AR and no signs of calcification. She was considered a poor choice for surgery or traditional TAVR due to multiple risks. That is where the new-look ATLAS technique came in.

READ MORE >
After traversing the aortic cusp with an electrified wire and balloon inflation, a stent is positioned inside the noncoronary cusp and deployed. Immediately after, a transcatheter aortic valve is expanded, and the stent is crushed on the left ventricular outflow tract wall and annulus, while anchored to the aortic valve leaflet.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists perform first TAVR of its kind by anchoring valve to crushed stent

Share on Twitter Share on Facebook Share on Linkedin
After traversing the aortic cusp with an electrified wire and balloon inflation, a stent is positioned inside the noncoronary cusp and deployed. Immediately after, a transcatheter aortic valve is expanded, and the stent is crushed on the left ventricular outflow tract wall and annulus, while anchored to the aortic valve leaflet.
The patient, 78, presented with severe AR and no signs of calcification. She was considered a poor choice for surgery or traditional TAVR due to multiple risks. That is where the new-look ATLAS technique came in.
READ MORE >

World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs

The new-look TAVR system was linked to multiple benefits after one year. The cardiologists evaluating this device belief it could significantly reduce the risk of long-term valve degeneration.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs

Share on Twitter Share on Facebook Share on Linkedin
The new-look TAVR system was linked to multiple benefits after one year. The cardiologists evaluating this device belief it could significantly reduce the risk of long-term valve degeneration.
READ MORE >

3D software helps cardiologists plan ahead for TAVR complications

Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues. 

READ MORE >
Matthew Summers, MD, FACC, program director for structural heart, Sentara Heart Hospital, Norfolk, Virginia, explains how his center used a new transcatheter aortic valve replacement (TAVR) 3D CT planning software to better identify patients who are at high risk of complications. The software also enables the heart team to test the best placement of various valves to create a procedure plan tailored for each patients unique anatomy.
Share on Twitter Share on Facebook Share on Linkedin

3D software helps cardiologists plan ahead for TAVR complications

Share on Twitter Share on Facebook Share on Linkedin
Matthew Summers, MD, FACC, program director for structural heart, Sentara Heart Hospital, Norfolk, Virginia, explains how his center used a new transcatheter aortic valve replacement (TAVR) 3D CT planning software to better identify patients who are at high risk of complications. The software also enables the heart team to test the best placement of various valves to create a procedure plan tailored for each patients unique anatomy.
Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues. 
READ MORE >

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

READ MORE >
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.
Share on Twitter Share on Facebook Share on Linkedin

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

Share on Twitter Share on Facebook Share on Linkedin
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 
READ MORE >

Moderate valve oversizing during TAVR boosts survival—too much may be less beneficial

Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.

READ MORE >
Newsweek ranked the 50 best heart hospitals in the world
Share on Twitter Share on Facebook Share on Linkedin

Moderate valve oversizing during TAVR boosts survival—too much may be less beneficial

Share on Twitter Share on Facebook Share on Linkedin
Newsweek ranked the 50 best heart hospitals in the world
Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.
READ MORE >

Cardiologists develop new AI screening tool for structural heart disease

Researchers have developed an advanced AI model capable of detecting signs of severe AS, mitral regurgitation and other complications in ECG results. For example, one 84-year-old patient who was hospitalized for a fractured femur ended up being scanned and treated with TAVR just days later.

READ MORE >
robot reviewing heart data
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists develop new AI screening tool for structural heart disease

Share on Twitter Share on Facebook Share on Linkedin
robot reviewing heart data
Researchers have developed an advanced AI model capable of detecting signs of severe AS, mitral regurgitation and other complications in ECG results. For example, one 84-year-old patient who was hospitalized for a fractured femur ended up being scanned and treated with TAVR just days later.
READ MORE >

FDA clears AI-powered platform that personalizes care during TAVR, cardiac pacing procedures

The newly cleared CARA System from Cara Medical was designed to help clinicians before and during a variety of cardiac procedures. It provides a personalized 3D map of the patient's cardiac conduction system and then overlays that map onto live fluoroscopic images.

READ MORE >
simulation of the conduction pathway relative to various cardiac structures.
Share on Twitter Share on Facebook Share on Linkedin

FDA clears AI-powered platform that personalizes care during TAVR, cardiac pacing procedures

Share on Twitter Share on Facebook Share on Linkedin
simulation of the conduction pathway relative to various cardiac structures.
The newly cleared CARA System from Cara Medical was designed to help clinicians before and during a variety of cardiac procedures. It provides a personalized 3D map of the patient's cardiac conduction system and then overlays that map onto live fluoroscopic images.
READ MORE >

TAVR a safe treatment option for patients who have undergone chest radiation therapy

In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation. 

READ MORE >
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Share on Twitter Share on Facebook Share on Linkedin

TAVR a safe treatment option for patients who have undergone chest radiation therapy

Share on Twitter Share on Facebook Share on Linkedin
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation. 
READ MORE >

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR

Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.

READ MORE >
cardiologist viewing heart data
Share on Twitter Share on Facebook Share on Linkedin

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR

Share on Twitter Share on Facebook Share on Linkedin
cardiologist viewing heart data
Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.
READ MORE >

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive. 

READ MORE >
A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Share on Twitter Share on Facebook Share on Linkedin
A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]
Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup